BioNexus begins VitaGuard MRD deployment in Southeast Asia; aims to undercut $3,000 legacy tests

BioNexus Gene Lab Corp

Initial deployments in select Southeast Asian medical hubs during 2026; platform targets under $3,000 per test vs legacy costs often exceeding $3,000.
Annual cancer incidence in region projected at 2.4M cases by 2030; company sees multi-billion-dollar market shift.
Fidelion Diagnostics Pte. Ltd. established as exclusive IP and commercialization vehicle outside Greater China.
Foundational steps completed by end 2025: global patent filings, recruitment, and regulatory prep with regional diagnostics partner.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.